We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips
Read MoreHide Full Article
Chemed’s (CHE - Free Report) Roto-Rooter business has been registering robust performance over the past few quarters. A good solvency position buoys optimism. Yet, headwinds like seasonality in business, competitive landscape and dependence on government mandates are intimidating. The stock carries a Zacks Rank #3 (Hold).
Over the past year, Chemed has outperformed its industry. The stock has gained 1.4% against the industry's 36.3% decline.
Chemed ended the second quarter of 2022 with better-than-expected earnings. The year-over-year growth in adjusted earnings per share appears promising. Robust performance by the Roto-Rooter segment drove the top line. The company recorded substantial increases in drain cleaning, plumbing, excavation and water restoration revenues in the quarter under review. The expansion of gross and operating margins instills optimism. The decline in operating costs is encouraging too.
Chemed’s nursing home admissions for the second quarter rose 5.3%. Assisted living facility admissions increased 5.6% and home-based pre-admit admissions grew 0.2% on a year-over-year basis. The company’s average length of stay in the reported quarter was 103.7 days, up from 94.5 days in the second quarter of 2021. The quarter’s median length of stay of 17 days compared favorably with the 14 days median length of stay in the year-ago period.
Chemed has been registering strong performance from the VITAS business over the past few quarters. Although the segment's revenues declined during the second quarter, it was somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%. The company’s second-quarter operating results reflected good earnings performance of the VITAS arm, which exceeded its internal estimates amid the persistent disruption from the pandemic.
The company’s latest admission data suggests that senior housing is in the process of stabilization and recovery. The company’s 2022 outlook anticipates a continued acceleration in the senior housing base census throughout the year.
On the flip side, Chemed’s VITAS revenues registered a 4.5% year-over-year decline in second-quarter 2022, raising apprehension. The VITAS arm continued to be challenged by pandemic-related issues, including health care labor shortages, disruption in senior housing occupancy and related hospice referrals. In the reported quarter, VITAS admissions totaled 14,735 patients, down 12.5% on a year-over-year basis. The company also witnessed a 20.5% decline in hospital-directed admissions compared to the year-ago period.
During the second quarter, Chemed’s average daily census was 17,315 patients, a decline of 3.8% year over year. Per management, this decline directly resulted from pandemic-related disruptions across the entire health care system since March 2020.
The deterioration in short-term cash levels is worrisome. The persistent macroeconomic headwinds related to the volatility in COVID-19 trends, rising inflationary pressure and other challenges continue to hamper business performance. A competitive landscape and reimbursement headwinds are other challenges.
Key Picks
Some better-ranked stocks in the broader medical space are ShockWave Medical (SWAV - Free Report) , McKesson (MCK - Free Report) and Semler Scientific . While ShockWave Medical sports a Zacks Rank #1 (Strong Buy), McKesson and Semler Scientific carry a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for ShockWave Medical have improved from earnings of $10.41 to $11.26 for 2022 and $7.94 to $8.30 for 2023 in the past 60 days. SWAV stock has gained 41.4% so far this year.
ShockWave Medical delivered an earnings surprise of 180.1%, on average, in the last four quarters.
McKesson’s earnings per share estimates increased from $23.26 to $24.25 for fiscal 2023 and $25.41 to $26.04 for fiscal 2024 in the past 60 days. MCK has gained 38.1% so far this year.
McKesson delivered an earnings surprise of 13.00%, on average, in the last four quarters.
Estimates for Semler Scientific’s earnings per share increased from $1.37 to $1.58 for 2022 and $2.39 to $2.42 for 2023 in the past 60 days. SMLR has declined 59.9% so far this year.
Semler Scientific has an earnings yield of 4% against a negative yield for the industry.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips
Chemed’s (CHE - Free Report) Roto-Rooter business has been registering robust performance over the past few quarters. A good solvency position buoys optimism. Yet, headwinds like seasonality in business, competitive landscape and dependence on government mandates are intimidating. The stock carries a Zacks Rank #3 (Hold).
Over the past year, Chemed has outperformed its industry. The stock has gained 1.4% against the industry's 36.3% decline.
Chemed ended the second quarter of 2022 with better-than-expected earnings. The year-over-year growth in adjusted earnings per share appears promising. Robust performance by the Roto-Rooter segment drove the top line. The company recorded substantial increases in drain cleaning, plumbing, excavation and water restoration revenues in the quarter under review. The expansion of gross and operating margins instills optimism. The decline in operating costs is encouraging too.
Chemed’s nursing home admissions for the second quarter rose 5.3%. Assisted living facility admissions increased 5.6% and home-based pre-admit admissions grew 0.2% on a year-over-year basis. The company’s average length of stay in the reported quarter was 103.7 days, up from 94.5 days in the second quarter of 2021. The quarter’s median length of stay of 17 days compared favorably with the 14 days median length of stay in the year-ago period.
Chemed has been registering strong performance from the VITAS business over the past few quarters. Although the segment's revenues declined during the second quarter, it was somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%. The company’s second-quarter operating results reflected good earnings performance of the VITAS arm, which exceeded its internal estimates amid the persistent disruption from the pandemic.
The company’s latest admission data suggests that senior housing is in the process of stabilization and recovery. The company’s 2022 outlook anticipates a continued acceleration in the senior housing base census throughout the year.
Chemed Corporation Price
Chemed Corporation price | Chemed Corporation Quote
On the flip side, Chemed’s VITAS revenues registered a 4.5% year-over-year decline in second-quarter 2022, raising apprehension. The VITAS arm continued to be challenged by pandemic-related issues, including health care labor shortages, disruption in senior housing occupancy and related hospice referrals. In the reported quarter, VITAS admissions totaled 14,735 patients, down 12.5% on a year-over-year basis. The company also witnessed a 20.5% decline in hospital-directed admissions compared to the year-ago period.
During the second quarter, Chemed’s average daily census was 17,315 patients, a decline of 3.8% year over year. Per management, this decline directly resulted from pandemic-related disruptions across the entire health care system since March 2020.
The deterioration in short-term cash levels is worrisome. The persistent macroeconomic headwinds related to the volatility in COVID-19 trends, rising inflationary pressure and other challenges continue to hamper business performance. A competitive landscape and reimbursement headwinds are other challenges.
Key Picks
Some better-ranked stocks in the broader medical space are ShockWave Medical (SWAV - Free Report) , McKesson (MCK - Free Report) and Semler Scientific . While ShockWave Medical sports a Zacks Rank #1 (Strong Buy), McKesson and Semler Scientific carry a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for ShockWave Medical have improved from earnings of $10.41 to $11.26 for 2022 and $7.94 to $8.30 for 2023 in the past 60 days. SWAV stock has gained 41.4% so far this year.
ShockWave Medical delivered an earnings surprise of 180.1%, on average, in the last four quarters.
McKesson’s earnings per share estimates increased from $23.26 to $24.25 for fiscal 2023 and $25.41 to $26.04 for fiscal 2024 in the past 60 days. MCK has gained 38.1% so far this year.
McKesson delivered an earnings surprise of 13.00%, on average, in the last four quarters.
Estimates for Semler Scientific’s earnings per share increased from $1.37 to $1.58 for 2022 and $2.39 to $2.42 for 2023 in the past 60 days. SMLR has declined 59.9% so far this year.
Semler Scientific has an earnings yield of 4% against a negative yield for the industry.